Imara is a clinical-stage biopharmaceutical company dedicated to developing novel therapeutics to treat patients suffering from rare inherited genetic disorders of hemoglobin, known as hemoglobinopathies. Our pipeline is built on the differentiated therapeutic potential of our initial product candidate, IMR-687, which is an oral, once-a-day, highly selective, potent small molecule inhibitor of PDE9 in development for sickle cell disease and beta-thalassemia. Sickle cell disease and beta-thalassemia have limited treatment options and are both characterized by severe symptoms and effects as well as reduced life expectancy.